Nikkei Asian Review reported that the company would cover some or all the cost of the therapy, Alofisel, which won EMA approval last year, if it did not provide benefit. The UK's NICE has declined to recommend it, citing modest benefit in a clinical trial.
The company expects reimbursement decisions by national-level authorities in 2019 and 2020. The UK's NICE recommended Cancer Drugs Fund coverage for another high-priced Novartis therapy, the CAR-T Kymriah, earlier this month.
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
NICE recommends Kymriah to the Cancer Drugs Fund due to remaining questions about evidence to support it, but believes those questions will be resolved.
The decision is not final, but the Swiss drugmaker's shares were down 1 percent in morning trading. NICE reached a similar decision last month on competitor Gilead's Yescarta.
Negotiations with country-level reimbursement authorities will follow. The UK's NICE turned down Gilead's Yescarta Tuesday.